Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bictegravir + emtricitabine + tenofovir alafenamide
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Biktarvy is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is a second-generation integrase strand transfer inhibitor (INSTI) with a high genetic barrier to resistance and a favorable safety profile. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit viral replication by acting as chain terminators. Developed by Gilead Sciences, Biktarvy is indicated as a complete single-tablet regimen for the treatment of HIV-1 infection in adults and pediatric patients. It is notable for its high efficacy, lack of requirement for a pharmacokinetic booster, and minimal drug-drug interactions compared to earlier protease inhibitor or cobicistat-boosted regimens. Clinical investigations continue to evaluate its use in infants, as post-exposure prophylaxis (PEP), and in patients with pre-existing NRTI resistance.
- Brand names
- Biktarvy
- Other names
- B/F/TAFBIC/FTC/TAFBictegravir/Emtricitabine/Tenofovir Alafenamide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePOLG (Mitochondrial DNA polymerase gamma)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on bictegravir + emtricitabine + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bictegravir + emtricitabine + tenofovir alafenamide.